Neil Kumar, Ph.D.
CEO and Founder
BridgeBio Pharma, Inc.
Dr. Neil Kumar, Ph.D., is the CEO and founder of BridgeBio Pharma, Inc., a company focused on the development of novel therapies for genetic diseases. Before founding BridgeBio in 2015, Dr. Kumar was a principal at Third Rock Ventures and an associate principal at McKinsey & Company. Dr. Kumar holds B.S. and M.S. degrees in chemical engineering from Stanford University. He received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.
Susan Moran, M.D., M.S.C.E.
Chief Medical Officer
QED Therapeutics, a BridgeBio Company
Dr. Susan Moran, M.D., M.S.C.E., is the chief medical officer at BridgeBio Pharma affiliate company QED Therapeutics. Dr. Moran has over 20 years of industry and academic experience, successfully leading clinical trials from Phase 1 to Phase 3, as well as marketing applications for various investigational products including the successful approval of Nerlynx. Before joining QED, she was VP and Head of Clinical Development for Puma Biotechnology and previously held senior positions at Millennium and Genzyme.
Ravi Savarirayan, M.D., Ph.D.
Group Leader of Skeletal Biology and Disease
Murdoch Children’s Research Institute, Melbourne, Australia
Dr. Ravi Savarirayan is a clinical geneticist with a primary clinical and research focus on the inherited disorders of the skeleton causing short stature, arthritis and osteoporosis.
He is the Foundation Director of the Southern Cross Bone Dysplasia Centre and immediate past-President of the International Skeletal Dysplasia Society (ISDS) and was the first Australian to hold this post. He has won numerous academic awards including the Fulbright Professional Scholarship for Australia.
Jonathan Fox, M.D., Ph.D., FACC
President and Chief Medical Officer
Eidos Therapeutics, Inc., a BridgeBio Company
Dr. Jonathan Fox, M.D., Ph.D., FACC, has served as President and Chief Medical Officer of Eidos Therapeutics and as the therapeutic area lead for cardiovascular and renal diseases at BridgeBio since 2016. Previously, Dr. Fox was the chief medical officer of MyoKardia, Inc. and held senior positions at SmithKline Beecham, Merck Research Laboratories and AstraZeneca LP. He was on the faculty of the University of Pennsylvania School of Medicine from 1993 to 2013.
Julian Gillmore, M.D., Ph.D.
Head, Centre for Amyloidosis & Acute Phase Proteins and NAC Research Lead
National Amyloidosis Centre, University College London
Professor Julian Gillmore undertook M.D. and Ph.D. degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis. He was appointed Centre Head at University College London’s Centre for Amyloidosis & Acute Phase Proteins in 2019 and is research lead at the UK National Amyloidosis Centre. He has published more than 250 peer-reviewed articles, has supervised a number of students through their post-doctoral research degrees, is CI/PI on a range of amyloid-related clinical trials, and has received extensive grant funding.
Eric David, M.D., J.D.
CEO in Residence
BridgeBio Gene Therapy
Dr. Eric David, M.D., J.D., is CEO of BridgeBio Gene Therapy. A co-founder of Organovo, he most recently served as the company’s chief strategy officer and executive vice president of preclinical development. Prior to Organovo, Dr. David was an associate partner at McKinsey & Co., an assistant professor at The Rogosin Institute, adjunct faculty at The Rockefeller University and a lecturer in Medicine at Weill Cornell Medical College. Dr. David received his clinical training in internal medicine at New York-Presbyterian / Weill Cornell.
Kyriakie Sarafoglou, M.D.
Associate Professor
University of Minnesota Medical School and College of Pharmacy
Dr. Kyriakie Sarafoglou, M.D., is an Associate Professor who holds appointments in the Department of Pediatrics, Divisions of Endocrinology and Genetics & Metabolism, University of Minnesota Medical School; and the Department of Experimental & Clinical Pharmacology, University of Minnesota College of Pharmacy. She specializes in rare endocrine and metabolic disorders holding multidisciplinary clinics that care for patients with congenital adrenal hyperplasia and disorders of sex development, hypophosphatasia, Turner syndrome and inborn errors of metabolism.
Michael Collins, M.D.
Chief of the Skeletal Disorders and Mineral Homeostasis Section
National Institutes of Health in Bethesda, Maryland
Dr. Michael Collins, M.D., is a physician scientist, trained in Endocrinology and Metabolism, whose research is broadly focused on the roles of PTH and FGF23 in bone biology and mineral homeostasis. Disease under investigation include fibrous dysplasia of bone/McCune-Albright syndrome, hypoparathyroidism, and disorders of FGF23 excess and deficiency such as x-linked hypophosphatemic rickets, tumor-induced osteomalacia, and familial tumoral calcinosis. Through detailed physiology studies and early phase clinical trials, he has made major contributions to understanding the pathophysiology of these conditions and significantly defined the standard of care of patients with these disorders.
Eli Wallace, Ph.D.
Chief Scientific Officer in Residence
BridgeBio Oncology
Dr. Eli Wallace, Ph.D., is BridgeBio Pharma’s Chief Scientific Officer in Residence for Oncology. Prior to joining BridgeBio, Dr. Wallace was Chief Scientific Officer at Peloton Therapeutics, where he and his team discovered and developed a first-in-class HIF2a inhibitor for renal cell carcinoma through clinical proof-of-concept. Dr. Wallace also worked as Director of Medicinal Chemistry at Array BioPharma, leading multiple research projects which produced eight new chemical entities that have entered human clinical trials for the treatment of cancer, including Mektovi®, which was approved to treat melanoma in 2018, Tukya®, which was approved to treat breast cancer in 2020, Koselugo®, which was approved to treat NF1 in 2020, and Akt inhibitor ipatasertib, which is currently in 2 phase 3 studies evaluating the treatment of prostate and breast cancers.
Frank McCormick, Ph.D., F.R.S., D.Sc.
Chairman of Oncology
BridgeBio Pharma, Inc.
Dr. Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) is BridgeBio’s Chairman of Oncology and a professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers. Dr. McCormick has previously worked at several biotechnology firms, including Cetus Corporation and Chiron Corporation. Dr. McCormick founded Onyx Pharmaceuticals in 1992.
Christine Siu
COO in Residence
BridgeBio Pharma, Inc.
Christine Siu is the Chief Operating Officer in Residence of BridgeBio. She formerly served as the Chief Financial Officer of Eidos Therapeutics, a BridgeBio company. Prior to that, Ms. Siu served as the chief business officer of the Bluefield Project to Cure Frontotemporal Dementia and was a venture principal at Third Rock Ventures, where she helped start Global Blood Therapeutics (GBT). Previously, she held roles of increasing responsibility at private equity and venture capital firms, Warburg Pincus and Thomas, McNerney & Partners, where she invested in life sciences companies.